Emma’s Story with OCREVUS SC

Watch Emma's story, from being diagnosed with MS to her experiences with OCREVUS treatment. Since 2018, Emma has been on OCREVUS IV therapy, and in 2024, she became the first patient in the UK to start on OCREVUS SC. This video provides Emma’s real life insights into her journey and the impact of her treatment on her day to day life.

This is an individual patient experience however patient experiences can vary.

Emma’s Story Continues - Reflections on her 2nd OCREVUS SC injection

Emma continues to share her real life experience following her 2nd OCREVUS SC injection. In this video, she reflects on the administration of the injection and her observations about her injection site afterwards. Emma provides further insights into her ongoing treatment journey and how OCREVUS SC continues to positively impact her life.

It is important for HCPs to ensure patients are informed about potential adverse events that may occur with OCREVUS. HCPs should refer to the Summary of Product Characteristics (SmPC) for a comprehensive list of these events.

References:

OCREVUS IV Summary of Product Characteristics
2. OCREVUS SC Summary of Product Characteristics

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.